Deka Biosciences

About Deka Biosciences

Deka Biosciences is dedicated to radically changing immunotherapy by developing personalized and precise treatments for cancer and inflammatory diseases through their innovative Diakine™ platform.

Products & Services

Diakine™ Platform:A next-generation cytokine therapy designed to treat inflammatory diseases and cancer by harnessing the immune system. It combines anti-inflammatory cytokines for inflammatory diseases or pairs immune-stimulating and anti-inflammatory cytokines for cancer treatment, targeting affected tissues for disease control.

Specialties

Immunotherapy Cytokine Therapy Cancer Treatment Inflammatory Disease Treatment Precision Medicine

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B2 T: - FT: Series B2	A: 20000000 MR: - FA: USD $20 Million FAN: 20000000	D: 2023-09-28 FD: 2023-09-28	9 investors

Series B2 Latest

2023-09-28

$20.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John Mumm

President & CEO

P

Pavel Khrimian

Co-Founder, Chief Business Officer

S

Stanley Frankel

Senior Clinical Advisor & Interim Chief Medical Officer

C

Christopher Yaen

General Counsel

D

Dave Boclair

Vice President, Technical Operations

D

Detlev Biniszkiewicz

Managing Director, MPM BioImpact

View 18 more team members with Pro

Unlock Full Team Directory

Recent News